Clinical Trial Update: Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tarlatamab in Chinese participants with extensive-stage small cell lung cancer after two or more prior lines of therapy; results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-15